CBDL: AI 评分 41/100 — AI 分析 (4月 2026)

CBD Life Sciences Inc. develops and markets cannabidiol (CBD) based organic products, including hemp drops, massage oils, and pain relief creams. The company operates in the specialty and generic drug manufacturing industry, focusing on CBD-infused consumer products and pet products.

Key Facts: AI Score: 41/100 Sector: Healthcare

公司概况

概要：

CBD Life Sciences Inc. is a small healthcare company focused on developing and marketing cannabidiol (CBD) based organic products, including hemp drops, massage oils, and pet products. Operating in the specialty and generic drug manufacturing industry, the company faces challenges with profitability and market competition.

CBDL是做什么的？

CBD Life Sciences Inc., based in Scottsdale, Arizona, develops and markets a range of cannabidiol (CBD) based organic products. The company's offerings include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. Founded to capitalize on the growing market for CBD-infused products, CBD Life Sciences aims to provide consumers with natural and organic alternatives for various health and wellness needs. The company focuses on creating products that leverage the potential therapeutic benefits of CBD. Its product line targets a diverse set of consumer needs, from pain relief and anxiety management to sleep improvement and pet care. CBD Life Sciences operates within the broader healthcare sector, specifically in the specialty and generic drug manufacturing industry, adapting its product offerings to meet evolving consumer preferences and regulatory requirements. Despite its efforts to establish a presence in the CBD market, CBD Life Sciences faces significant challenges, including negative profit margins and intense competition. The company's ability to navigate these challenges and achieve sustainable growth will depend on its success in product innovation, marketing effectiveness, and operational efficiency.

CBDL的投资论点是什么？

Investing in CBD Life Sciences Inc. (CBDL) presents significant risks due to its current financial standing and competitive landscape. With a negative profit margin of -905.5% and a negative gross margin of -9.9%, the company's financial viability is questionable. The company's high beta of -3603.52 indicates extreme volatility, making it a speculative investment. Potential growth catalysts include successful product innovation and market expansion, but these are highly uncertain. The company's small size, with only 3 employees, limits its operational capacity. Investors should carefully consider these factors and conduct thorough due diligence before considering an investment in CBDL. The lack of a dividend yield further reduces the attractiveness of the stock for income-seeking investors.

CBDL在哪个行业运营？

CBD Life Sciences Inc. operates in the rapidly evolving market for cannabidiol (CBD) products. The industry has experienced substantial growth due to increasing consumer interest in natural health and wellness solutions. However, the market is highly competitive, with numerous companies offering similar products. Regulatory uncertainty and varying state laws add complexity to the business environment. CBD Life Sciences competes with both established pharmaceutical companies and smaller, specialized CBD product manufacturers. The company's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.

Drug Manufacturers - Specialty & Generic

Healthcare

CBDL有哪些增长机遇？

Expansion of Product Line: CBD Life Sciences can expand its product line to include new CBD-infused products targeting specific health conditions or wellness needs. The market for CBD products is projected to reach $16 billion by 2026, providing ample opportunity for growth. Success depends on effective research and development to create innovative and differentiated products, giving the company a competitive edge.
Strategic Partnerships: Forming strategic partnerships with established healthcare or retail companies can provide CBD Life Sciences with access to new markets and distribution channels. Collaborating with larger companies can enhance brand visibility and credibility. The timeline for realizing benefits from partnerships depends on the negotiation and implementation process, but strategic alliances can drive growth within the next 1-2 years.
Online Sales and Marketing: Enhancing its online presence and marketing efforts can help CBD Life Sciences reach a broader customer base. Investing in e-commerce platforms, social media marketing, and search engine optimization can drive online sales. The global e-commerce market is expected to continue growing, offering significant opportunities for CBD Life Sciences to expand its online sales channels and increase revenue.
International Expansion: Expanding into international markets, particularly in Europe and Asia, can provide CBD Life Sciences with new growth opportunities. The global market for CBD products is expanding, and entering new geographic regions can diversify revenue streams. However, international expansion requires careful consideration of regulatory requirements and cultural differences, which may take 2-3 years to fully implement.
Focus on Pet Products: The market for CBD pet products is growing rapidly, as pet owners seek natural solutions for their animals' health and wellness. CBD Life Sciences can capitalize on this trend by expanding its line of pet products and marketing them to pet owners. The pet care industry is expected to continue growing, providing a favorable environment for CBD Life Sciences to increase its market share in the pet product segment.

Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
P/E ratio of -0.64 reflects negative earnings, suggesting the company is not currently profitable.
Profit Margin of -905.5% highlights significant operational inefficiencies and challenges in generating profit.
Gross Margin of -9.9% indicates that the company's cost of goods sold exceeds its revenue, posing a threat to long-term sustainability.
Beta of -3603.52 suggests the stock is highly volatile and moves inversely to the market, increasing investment risk.

CBDL提供哪些产品和服务？

Develops cannabidiol (CBD) based organic products.
Markets hemp drops for general wellness.
Offers massage oils for relaxation and therapeutic purposes.
Provides recovery pain relief creams for muscle and joint pain.
Sells anxiety and sleep solutions supplements.
Markets CBD-infused edibles.
Offers a line of pet products containing CBD.

CBDL如何赚钱？

Develops and manufactures CBD-based products.
Markets products directly to consumers through online channels.
Generates revenue through the sale of CBD-infused products.

Individuals seeking natural health and wellness solutions.
Consumers looking for pain relief and anxiety management products.
Pet owners seeking CBD products for their pets.

Proprietary formulations for CBD-infused products.
Focus on organic and natural ingredients.
Brand reputation for quality and effectiveness (if established).

什么因素可能推动CBDL股价上涨？

Upcoming: Potential regulatory changes in the CBD market could create new opportunities or challenges.
Ongoing: Increasing consumer awareness and acceptance of CBD products may drive demand.
Ongoing: Development and launch of new CBD-infused products targeting specific health conditions.
Ongoing: Strategic partnerships with established healthcare or retail companies to expand market reach.

CBDL的主要风险是什么？

Potential: Intense competition in the CBD market could erode market share and profitability.
Ongoing: Regulatory uncertainty and varying state laws create compliance challenges.
Potential: Changes in consumer preferences or negative publicity could reduce demand for CBD products.
Ongoing: The company's negative profit and gross margins pose a threat to its financial sustainability.
Potential: Limited access to capital may hinder growth and expansion efforts.

CBDL的核心优势是什么？

Focus on cannabidiol (CBD) based organic products.
Diverse product line including hemp drops, massage oils, and pet products.
Potential for growth in the expanding CBD market.

CBDL的劣势是什么？

Negative profit margin of -905.5%.
Negative gross margin of -9.9%.
Small number of employees (3), limiting operational capacity.
High beta of -3603.52 indicating extreme volatility.

CBDL有哪些机遇？

Expansion of product line to target specific health conditions.
Strategic partnerships with established healthcare or retail companies.
Increased online sales and marketing efforts.
Expansion into international markets.

CBDL面临哪些威胁？

Intense competition in the CBD market.
Regulatory uncertainty and varying state laws.
Potential changes in consumer preferences.
Economic downturn affecting consumer spending.

CBDL的竞争对手是谁？

American Oil & Gas, Inc. — Focuses on oil and gas exploration and production. — (AOXG)
Earth Technologies, Inc. — Engages in environmental and industrial services. — (ETBI)
Green Power Fasteners, Inc. — Manufactures and distributes fasteners. — (GPFT)
Health Products Mktg. Corp. — Markets and distributes health and wellness products. — (HPMM)
Invictus MD Strategies Corp. — Focuses on the cannabis industry. — (IVIXF)

Key Metrics

MoonshotScore: 41/100

Company Profile

CEO: Lisa Anne Nelson
Headquarters: Scottsdale, US
Employees: 3
Founded: 2009

AI Insight

AI analysis pending for CBDL

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CBD Life Sciences Inc. do?

CBD Life Sciences Inc. engages in the development and marketing of cannabidiol (CBD) based organic products. Its product line includes hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company focuses on providing natural and organic alternatives for various health and wellness needs, targeting consumers seeking the potential therapeutic benefits of CBD. CBD Life Sciences operates within the specialty and generic drug manufacturing industry.

What do analysts say about CBDL stock?

There is currently no available analyst coverage for CBD Life Sciences Inc. (CBDL) due to its small market capitalization and OTC listing. Key valuation metrics such as price-to-earnings ratio (P/E) and price-to-sales ratio (P/S) are either negative or not meaningful due to the company's current financial performance. Investors should conduct their own thorough analysis and consider the company's financial risks and growth potential before making any investment decisions. The lack of analyst coverage reflects the speculative nature of this investment.

What are the main risks for CBDL?

The main risks for CBD Life Sciences Inc. include its negative profit margin of -905.5% and negative gross margin of -9.9%, indicating significant financial challenges. The company also faces intense competition in the rapidly evolving CBD market, as well as regulatory uncertainty and varying state laws. Its small size, with only 3 employees, limits its operational capacity. Additionally, the company's OTC listing and high beta of -3603.52 indicate increased volatility and investment risk. These factors collectively pose substantial risks to investors.